← Leaderboards
James W Rocco
Massachusetts General Hospital
$3,486,054
Attributed
$3,486,054
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $821K · FY2006–15$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$3,486,054 · 2
By mechanism
R01$2,897,708 · 1
R21$588,346 · 1
Top collaborators
No co-investigators on record.
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Peter D Caravan$27,832,958
- Iris Yuwen Zhou$931,639
- Daniel S Kohane$17,057,196
- Sydney Montesi$2,223,234
- Rakesh K. Jain$48,476,214
Others in their field
Top investigators on “Head And Neck Cancer”
- Walter John Curran · Thomas Jefferson University$111,090,486
- Norman Wolmark · Nsabp Foundation, Inc.$59,047,729
- David Heimbrook · Leidos Biomedical Research, Inc.$56,561,099
- Robert S Mannel · University Of Oklahoma Hlth Sciences Ctr$42,566,636
- Charles A Coltman · Southwest Oncology Group$36,988,659
- James J. Dignam · University Of Chicago$35,003,821
Research focus
Head And Neck CancerTumorChemotherapyRecurrenceResponseSmall MoleculeResistanceDrinkingApoptoticFutureBinding (Molecular Function)Biochemical MarkersAccountingDesignComplementEpidemicFunctional StatusClinical TreatmentBaseCohortCisplatinClassificationClinical PracticeCytotoxic Chemotherapy
Grant awards (8)
Bcl-2 as a Biomarker for Prognosis and Therapy of Head and Neck Cancer$662,650
R01 · FY2015 · DE · contact PI
Bcl-2 as a Biomarker for Prognosis and Therapy of Head and Neck Cancer$820,972
R01 · FY2014 · DE · contact PI
Bcl-2 as a Biomarker for Prognosis and Therapy of Head and Neck Cancer$412,075
R01 · FY2013 · DE · contact PI
Bcl-2 as a Biomarker for Prognosis and Therapy of Head and Neck Cancer$122,000
R01 · FY2013 · DE · contact PI
Bcl-2 as a Biomarker for Prognosis and Therapy of Head and Neck Cancer$429,547
R01 · FY2012 · DE · contact PI
Bcl-2 as a Biomarker for Prognosis and Therapy of Head and Neck Cancer$450,464
R01 · FY2011 · DE · contact PI
Phase II Clinical Trial of AZD2171 Monotherapy In Recurrent Head and Neck Cancer$289,845
R21 · FY2007 · CA · contact PI
Phase II Clinical Trial of AZD2171 Monotherapy In Recurrent Head and Neck Cancer$298,501
R21 · FY2006 · CA · contact PI